Streetbeat News

Earnings

TNYA

Tenaya Therapeutics (NASDAQ:TNYA) reported Q4 earnings with losses of $(0.40) per share, surpassing the analyst consensus estimate of $(0.44) by 9.09%. This represents a 34.43% improvement over the previous year's losses of $(0.61) per share.

Portfolio Pulse from Happy Mohamed

March 18, 2024 | 8:09 pm

MOTS

Motus GI Holdings (MOTS) reported Q4 earnings with a loss of $4.48 per share, missing the consensus estimate of $4.39, and sales of $64K, also missing the estimate of $150K. This represents a 62.19% improvement in losses and a 41.28% decrease in sales year-over-year.

Portfolio Pulse from Happy Mohamed

March 18, 2024 | 8:08 pm

REYN

Reynolds Consumer Products has reaffirmed its financial guidance for both Q1 2024 and the full year of 2024. Additionally, the company has introduced its vision for the year 2030, outlining its long-term strategic goals.

Portfolio Pulse from Benzinga Newsdesk

March 18, 2024 | 8:06 pm

AUGX

Augmedix reported Q4 2023 earnings with a GAAP EPS of $(0.09), surpassing the $(0.10) estimate. Sales reached $12.680M, exceeding the $12.466M forecast and marking a 44.90% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

March 18, 2024 | 8:05 pm

DLO

DLocal reported Q4 2023 earnings with a GAAP EPS of $0.10, missing the $0.15 estimate, but sales of $188M exceeded the $173.686M forecast, marking a 58.75% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

March 18, 2024 | 8:03 pm

PMVP

PMV Pharmaceuticals presented promising Phase 1 data of rezatapopt in advanced ovarian cancer at the 2024 SGO Annual Meeting. The study showed a confirmed partial response in 7 out of 15 patients, with a median duration of response of seven months and a favorable safety profile. Rezatapopt targets TP53 Y220C mutation and KRAS wild-type in advanced solid tumors and is advancing to a registrational Phase 2 study.

Portfolio Pulse from Benzinga Newsdesk

March 18, 2024 | 8:02 pm

IVA

Inventiva announced positive results from its Phase II LEGEND study on lanifibranor combined with empagliflozin in treating MASH/NASH and T2D. The study met its primary efficacy endpoint, showing significant reductions in HbA1c levels, liver injury markers, and hepatic steatosis. Both treatments were well tolerated with no safety concerns. Inventiva will host an investor webcast to discuss these results.

Portfolio Pulse from Benzinga Newsdesk

March 18, 2024 | 8:01 pm

XPEV

XPeng (NYSE:XPEV) is scheduled to release its quarterly earnings report on March 19, 2024, with analysts expecting an EPS of $-0.46. Despite past earnings beats, XPeng's share price has experienced declines following earnings announcements. Shares are currently trading at $9.64, reflecting a 1.06% decrease over the last year. Investors are particularly focused on the company's guidance for future growth.

Portfolio Pulse from Benzinga Insights

March 18, 2024 | 8:00 pm

S

SentinelOne shares are trading higher, potentially rebounding from a recent drop following their Q4 earnings report.

Portfolio Pulse from Benzinga Newsdesk

March 18, 2024 | 7:49 pm

HON

Recent options trading activity indicates a bearish sentiment towards Honeywell Intl (NASDAQ:HON), with a notable volume of trades suggesting expectations of price movements between $185.0 and $210.0. The trading activity, comprising both puts and calls, shows a split sentiment among big-money investors. Honeywell, a diversified technology and manufacturing company, has seen its stock price slightly increase by 0.61% to $198.9. An analyst from Berenberg has recently upgraded Honeywell to Buy with a price target of $240. The company is expected to announce its earnings in 38 days.

Portfolio Pulse from Benzinga Insights

March 18, 2024 | 7:46 pm